NEW YORK, June 5, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023 and May 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2025.So What: If you purchased UroGen securities during the Class Period you ma ...

SAN FRANCISCO, June 5, 2025 /PRNewswire/ -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025.The lawsuit comes after investors saw the price of their shares in UroGen Pharma Ltd. (NASDAQ: URGN) crash on May 16, 2025 as a result of the FDA's publication of a briefing document a few days before an upcoming Oncolo ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. ("UroGen Pharma Ltd." or the "Company") (NASDAQ: URGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UroGen Pharma Ltd. investors who were adversely affected by alleged securities fraud between July 27, 2023 and May 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/urogen-p ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) (“UroGen” or the “Company”) The lawsuit is on behalf of individuals or entities that purchased or acquired UroGen Pharma Ltd. securities between July 27, 2023 and May 15, 2025 (the “Class Period”). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations The lawsuit alleges that during the Class Pe ...

NEW YORK, June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN). Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rig ...

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025. The lawsuit comes after investors saw the price of their shares in UroGen Pharma Ltd. (NASDAQ: URGN) crash on May 16, 2025 as a result of the FDA’s publication of a briefing document a few days before an upcoming ...

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR UROGEN INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In UroGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in UroGen between July 27, 2023 and May 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ -- Faru ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit. Investors have until July 28, 2025, to ask the Court ...

公司诉讼案件 - UroGen Pharma Ltd因涉嫌违反1934年证券交易法被集体诉讼 指控涉及2023年7月27日至2025年5月15日期间购买或收购其证券的投资者 [1] - 诉讼指控公司及其高管在Class Period内作出虚假或误导性陈述 或未披露关键信息 [3] - 主要指控包括ENVISION临床研究设计缺陷 未能证明UGN-102有效性 且忽视FDA关于研究设计的警告 [3] 产品与研发 - UroGen专注于开发治疗特殊癌症的解决方案 主导产品UGN-102(丝裂霉素)为治疗低级别中危非肌层浸润性膀胱癌的膀胱内溶液 [2] - FDA在2025年5月16日简报文件中指出ENVISION研究缺乏并行对照组 导致主要终点(完全缓解率和缓解持续时间)难以解释 [4] - 2025年5月21日肿瘤药物咨询委员会投票反对UGN-102新药申请 认为其风险收益比不利 [5] 市场反应 - FDA简报文件公布后 UroGen股价单日下跌近26% [4] - 新药申请被委员会否决后 股价进一步下跌45% [5] 法律程序 - 根据1995年私人证券诉讼改革法 投资者可在2025年7月28日前申请成为首席原告 [1][6] - 首席原告需为拟议集体中财务利益最大且具代表性的成员 将主导诉讼进程并选择律师事务所 [6] 律师事务所背景 - Robbins Geller律所在证券欺诈诉讼领域领先 过去五年中有四年在ISS证券集体诉讼服务排名中位列第一 [7] - 2024年为投资者追回超过25亿美元赔偿 金额超过其他五家律所总和 [7] - 曾创下72亿美元的历史最大证券集体诉讼赔偿纪录(安然公司案) [7]